ELAN Q2 2026 Earnings Call Summary

Summary of Elanco Animal Health Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Revenue: $1.368 billion, up 10% year-over-year; organic constant currency revenue growth of 8%.
Adjusted EBITDA: $288 million, a 21% increase year-over-year.
Adjusted EPS: $0.34, a 31% increase year-over-year.
Gross Margin: 58.1%, an improvement of 80 basis points from the previous year.
Net Leverage Ratio: Reduced to 3.1x, with a target of approximately 3x by year-end.

2. Strategic Updates and Business Highlights

Growth Drivers:
- U.S. Pet Health and U.S. Farm Animal segments each grew by 11%.
- International Pet Health grew by 9%, driven by strong performance from Zenrelia and Credelio Quattro.
- Innovation revenue reached $340 million, with a revised full-year target for innovation revenue raised to $1.25 billion.
Product Highlights:
- Zenrelia is now a blockbuster, with over 2.5 million dogs treated and significant market share gains.
- Credelio Quattro saw a 4-point market share increase in Q2, with expansion into new markets including Australia and Japan.
- AdTab, an OTC parasiticide, grew over 30% and is on track to become a blockbuster.
Elanco Ascend Initiative: A multiyear productivity program aimed at achieving $200 million to $250 million in adjusted EBITDA savings by 2030.

3. Forward Guidance and Outlook

Full-Year Guidance:
- Organic constant currency revenue growth revised to 6% to 7%.
- Adjusted EBITDA guidance increased to $1.01 billion to $1.035 billion, reflecting a 13% growth at the midpoint.
- Adjusted EPS guidance raised to $1.10 to $1.16, a 20% growth at the midpoint.
Q3 Expectations: Anticipated revenue of $1.195 billion to $1.22 billion, with organic constant currency growth of 5% to 7%.

4. Bad News, Challenges, or Points of Concern

Competitive Pressures: Increased competition in the market, particularly in the derm and parasiticide segments, with competitors also raising prices.
Inflationary Pressures: Continued inflation affecting costs, although gross margin improvements are expected.
Market Dynamics: While the U.S. Pet Health market is growing, there are concerns regarding the overall decline in vet visit volumes, which may impact long-term growth.

5. Notable Q&A Insights

Pricing Environment: Management indicated that pricing remains responsible and is expected to accelerate in the second half of the year, despite competitive pressures.
OpEx Management: Operating expenses are expected to continue rising due to investments in DTC marketing and innovation, but long-term operating leverage is anticipated as productivity initiatives take effect.
Market Share Gains: Significant share gains for Zenrelia and Credelio Quattro were highlighted, with expectations for continued growth driven by effective marketing and product differentiation.
Future Growth: Management expressed confidence in the long-term potential of both the Pet Health and Farm Animal segments, citing strong demand for high-quality protein and innovative products.

This summary encapsulates the key aspects of Elanco's Q2 2026 earnings call, presenting a balanced view of their financial performance, strategic initiatives, and market outlook while addressing potential challenges.

ELAN — Elanco Animal Health Incorporated